FDA
-
-
-
-
-
-
-
Aura Biosciences adds former Day One CEO to its board
-
-
-
-
-
-
-
Mereo BioPharma Provides Corporate Update
-
-
-
-
-
-
-
āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2
-
-
-
-
-
-
-
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference
-
-
-
-
-
-
-
Mereo BioPharma (MREO) Prices 12.53M Share Offering at $3.99/sh
-
-
-
-
-
-
-
Mereo BipPharma Group (MREO) PT Raised to $6 at Needham on increased 'launch expectations for setrusumab in OI'
-
-
-
-
-
-
-
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (
-
328,599 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

